Retinal Disease clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Advanced Vision Loss (Sirius)
open to eligible people ages 12 years and up
The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with advanced vision loss.
San Francisco, California and other locations
Our lead scientists for Retinal Disease research studies include Jacque Duncan, MD.
Last updated: